Pathfinder Cell Therapy IncOver The Counter Market:PFND
- LAST PRICE0.0000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.0000
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Pathfinder Cell Therapy Inc | 670.0 | 0.0x | --- |
Gene Biotherapeutics Inc | 60.0 | 0.0x | --- |
Refocus Group Inc | 20.0 | 0.0x | --- |
Allon Therapeutics Inc | 14.1K | 0.0x | --- |
Easton Pharmaceuticals Inc | 1.3K | 0.0x | --- |
Miravant Medical Technologies | 40.0 | 0.0x | --- |
Company Information
Pathfinder Cell Therapy, Inc. is a regenerative medicine company. The Company is seeking to develop cell-based and related therapies for the treatment of a range of diseases and medical conditions characterized by organ-specific cell damage. The Company is engaged in developing cell-based therapy for the treatment of diabetes, renal disease, myocardial infarction and other diseases characterized by organ-specific cell damage. The Company has discovered a mammalian cell type, which is able to stimulate damaged tissues to regenerate without the Pathfinder Cells (PCs) themselves being incorporated into the new tissue. PCs have shown efficacy in approximately three different animal models of diabetes, cardiac ischemia and renal reperfusion injury. The Company has tested these models for PCs from both rat and human sources. As of September 30, 2015, the Company had no revenue generated.
Contact Information
- Headquarters
- 12 Bow StCAMBRIDGE, MA, United States 02138
- Phone
- 617-245-0289
- Fax
- ---
Executives
- Chairman of the Board
- Joerg Gruber
- President, Chief Executive Officer, Secretary, Director
- Richard Franklin
- Chief Financial Officer, Treasurer
- John Benson
- Independent Director
- John Alam
- Independent Director
- John Brooks
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $670.00 |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 667.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $0.00 |
Book Value | $-0.01 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
